119 related articles for article (PubMed ID: 31418750)
1. Toxic epidermal necrolysis (Lyell syndrome) as a severe and fatal manifestation of multiple myeloma with amyloidosis in a patient with rapidly progressing end-stage renal disease.
Kępska-Dzilińska M; Kohmann A; Kuriga M; Puła B; Matuszkiewicz-Rowińska J; Małyszko J
Pol Arch Intern Med; 2019 Nov; 129(11):819-821. PubMed ID: 31418750
[No Abstract] [Full Text] [Related]
2. Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.
Moore DC; Arnall JR; Janes A; Pineda-Roman M
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e395-e398. PubMed ID: 32359768
[No Abstract] [Full Text] [Related]
3. Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
Hwang S; Woo Y; Kim M; Park HJ
Int J Dermatol; 2017 Feb; 56(2):e35-e37. PubMed ID: 27805271
[No Abstract] [Full Text] [Related]
4. Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.
Krečak I; Ruščić I; Zlatović JJ; Šupe M; Krečak MV; Gverić-Krečak V
Ann Hematol; 2021 Jun; 100(6):1623-1624. PubMed ID: 33404692
[No Abstract] [Full Text] [Related]
5. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Fang B; Song Y; Ma J; Zhao RC
Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
[No Abstract] [Full Text] [Related]
6. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.
Noto R; Kamiura N; Ono Y; Tabata S; Hara S; Yokoi H; Yoshimoto A; Yanagita M
BMC Nephrol; 2017 Apr; 18(1):127. PubMed ID: 28385149
[TBL] [Abstract][Full Text] [Related]
7. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Boruah PK; Bolesta S; Shetty SM
Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
9. Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that 'toxic' epidermal necrolysis can be 'non-toxic'.
Dumas M; Hua C; Hotz C; Velter C; Duong TA; Maraffi T; Ortonne N; Hüe S; Fardet L; de Prost N; Wolkenstein P; Ingen-Housz-Oro S; Chosidow O
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):e360-e361. PubMed ID: 29524279
[No Abstract] [Full Text] [Related]
10. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
[No Abstract] [Full Text] [Related]
11. The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.
Hashimoto S; Kuroha T; Yano T; Sato N; Furukawa T
Intern Med; 2016; 55(20):3025-3028. PubMed ID: 27746443
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
[No Abstract] [Full Text] [Related]
13. Toxic epidermal necrolysis induced by vemurafenib.
Lapresta A; Dotor A; González-Herrada C
Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
[No Abstract] [Full Text] [Related]
14. Bortezomib-induced cardiogenic shock in a multiple myeloma patient with K light-chain cardiac amyloidosis.
Dammassa V; Greco A; Totaro R; Colombo CNJ; Raineri C; Camporotondo R; De Ferrari GM; Mojoli F; Arbustini E; Oltrona Visconti L; Tavazzi G
Ann Hematol; 2022 Sep; 101(9):2087-2088. PubMed ID: 35538262
[No Abstract] [Full Text] [Related]
15. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
Nayar N; Briscoe K; Fernandez Penas P
J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
[TBL] [Abstract][Full Text] [Related]
16. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib.
Nühnen VP; Schön MP; Mössner R
J Dtsch Dermatol Ges; 2018 Feb; 16(2):199-201. PubMed ID: 29328518
[No Abstract] [Full Text] [Related]
17. Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.
Das A; Sil A; Mishra V; Das NK
Indian J Pharmacol; 2014; 46(5):557-9. PubMed ID: 25298592
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide in the treatment of toxic epidermal necrolysis.
Frangogiannis NG; Boridy I; Mazhar M; Mathews R; Gangopadhyay S; Cate T
South Med J; 1996 Oct; 89(10):1001-3. PubMed ID: 8865797
[TBL] [Abstract][Full Text] [Related]
19. Use of bisphosphonates in patients with myeloma and renal failure.
Saghafi D
Mayo Clin Proc; 2003 Jan; 78(1):118; author reply 118. PubMed ID: 12528887
[No Abstract] [Full Text] [Related]
20. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer.
Urosevic-Maiwald M; Harr T; French LE; Dummer R
Int J Dermatol; 2012 Jul; 51(7):864-7. PubMed ID: 22715836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
